BeiGene company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

beigene.com

Executives

8

BeiGene Management Team

8 Team Members

BeiGene has 8 executives. BeiGene's founder is Pearl Huang. BeiGene's current Founder, Chief Executive Officer is John V Oyler.

Name

Work History

Title

Status

Pearl Huang

Cygnal Therapeutics, Roche Venture Fund, GSK, Merck & Co., DuPont, and Merck Research Ventures Fund

Founder

Current

John V Oyler

Founder, Chief Executive Officer

Current

Lusong Luo

Senior Vice President

Current

Jason Yang

Senior Vice President

Current

Wendy Yan

Managing General Partner

Current

Name

Pearl Huang

John V Oyler

Lusong Luo

Jason Yang

Wendy Yan

Work History

Cygnal Therapeutics, Roche Venture Fund, GSK, Merck & Co., DuPont, and Merck Research Ventures Fund

Title

Founder

Founder, Chief Executive Officer

Senior Vice President

Senior Vice President

Managing General Partner

Status

Current

Current

Current

Current

Current

You May Also Like

G
Guangzhou Baiyunshan Pharmaceutical

Guangzhou Baiyunshan Pharmaceutical specializes in the development and production of Chinese patent medicines, biological products, health medicines, and health beverages, as well as the wholesale, retail, import, and export of Chinese medicine, western medicine, and medical equipment. It is based in Guangzhou, Guangdong.

D
Delova Biotech

Delova Biotech is a specialty branded pharmaceutical company, focusing on the development of proprietary formulations of injectable drug products to fulfill unmet medical needs in China and the US. The firm was founded in 2017 and is based in Nanjing, China.

H
Hua Medicine

Hua Medicine (华领医药) (HK: 02552) is a clinical-stage drug development company in China, focusing on therapies for the treatment of diabetes and CNS disorders.

Sinopharm Logo
Sinopharm

China National Pharmaceutical Group is a Chinese medical and healthcare group directly managed by State-owned Assets Supervision and Administration Commission of the State Council (SASAC). Sinopharm's core businesses include distribution, retail, scientific research, and manufacture of healthcare-related products and owns wholly-owned or holding subsidiaries, and companies, including Sinopharm Group, China National Medicines, Sinopharm Accord Medicines, Tiantan Biological Products, Shanghai Shyndec Pharmaceutical, and China Traditional Chinese Medicine.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.